Kimball Bailey, DO
Internal Medicine · Draper, UTNPI 1073176400
Payments from drug & device makers
Across 160 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$449
- AbbVie$383
- Lilly USA, LLC$257
- Corcept Therapeutics$191
- Phathom Pharmaceuticals, Inc.$147
- Pfizer$144
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,007100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 17 | $449 |
| AbbVie | 21 | $383 |
| Lilly USA, LLC | 15 | $257 |
| Corcept Therapeutics | 9 | $191 |
| Phathom Pharmaceuticals, Inc. | 11 | $147 |
| Pfizer | 8 | $144 |
| Grifols USA, LLC | 6 | $128 |
| Novo Nordisk | 7 | $112 |
| Idorsia Pharmaceuticals US Inc | 6 | $109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $101 |
| AstraZeneca | 6 | $91 |
| Exact Sciences | 5 | $81 |
| Corium, LLC | 5 | $77 |
| Inspire Medical Systems, Inc. | 3 | $64 |
| GSK | 4 | $64 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $55 |
| Radius Health, Inc. | 3 | $54 |
| Dynavax Technologies Corporation | 3 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Shield Therapeutics Inc | 2 | $41 |
| Sanofi | 2 | $40 |
| Johnson & Johnson | 2 | $34 |
| Boehringer Ingelheim | 2 | $34 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Mayne Pharma Commercial LLC | 1 | $24 |
| Edwards Lifesciences | 1 | $23 |
| Electromed, Inc. | 2 | $21 |
| Boston Scientific | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Recor Medical Inc | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Kaleo, Inc. | 1 | $16 |
| Abbott | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$134
How this compares
$3,007 in reported general payments places this provider in the 80th percentile of 496 internal medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 66 | $89,353 |
| OzempicSemaglutide | 34 | $61,836 |
| JardianceEmpagliflozin | 38 | $61,703 |
| FarxigaDapagliflozin Propanediol | 43 | $49,419 |
| RybelsusSemaglutide | 15 | $36,835 |
| Nurtec OdtRimegepant Sulfate | 18 | $32,069 |
| TymlosAbaloparatide | 12 | $31,228 |
| EliquisApixaban | 27 | $30,868 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $13,610 |
| AlvescoCiclesonide | 18 | $5,643 |
| Bupropion XlBupropion Hcl | 33 | $2,777 |
| Celecoxib | 33 | $2,427 |
| Losartan Potassium | 176 | $2,292 |
| Levothyroxine Sodium | 188 | $2,163 |
| Atorvastatin Calcium | 200 | $2,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $112 | $98,67149 claims |
| Lilly USA, LLCMounjaro | $257 | $89,35366 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $91 | $63,03061 claims |
| PfizerNurtec Odt, Eliquis | $144 | $62,93645 claims |
| Boehringer IngelheimJardiance | $34 | $61,70338 claims |
| Radius Health, Inc.Tymlos | $54 | $31,22812 claims |
| AbbVieSynthroid | $383 | $1,42715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 496 internal medicine providers in Utah.
Other internal medicine in Draper
- Kevin TschetterDraper$8K
- Ahad SabetSalt Lake City$34.5M
- Barbara RizzardiSandy$27.8M
- Willard DereSalt Lake City$4.7M
- Joseph WoolleySaint George$3.6M
- Justin MansfieldOgden$3.1M
- Michael KillpackSandy$2M
- Cuper Martinez SantibanezWest Valley City$1M
- Joshua OaksBountiful$973K
- Brandon WebbSalt Lake City$544K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.